FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Semaglutide (WEGOVY®) Injection
Status: Currently in Shortage
»Date first posted: 03/31/2022
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Novo Nordisk, Inc. (Revised 04/22/2022)

Company Contact Information:
833-493-4689

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
0.25 mg / 0.5mL (NDC 0169-4525-14) Distribution of this dose temporarily paused, resumption of supply expected 2nd half 2022 Requirements related to complying with good manufacturing practices.
0.5 mg / 0.5mL (NDC 0169-4505-14) Distribution of this dose temporarily paused, resumption of supply expected 2nd half 2022 Requirements related to complying with good manufacturing practices.
1 mg / 0.5mL (NDC 0169-4501-14) Currently unavailable, resumption of supply expected 2nd half 2022 Requirements related to complying with good manufacturing practices.
1.7 mg / 0.75mL (NDC 0169-4517-14) Currently available Requirements related to complying with good manufacturing practices.
2.4 mg / 0.75mL (NDC 0169-4524-14) Currently available Requirements related to complying with good manufacturing practices.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English